Roivant Sciences Ltd. (NASDAQ:ROIV – Get Rating) fell 2.5% during mid-day trading on Friday . The company traded as low as $7.89 and last traded at $7.90. 201,439 shares were traded during mid-day trading, a decline of 92% from the average session volume of 2,543,887 shares. The stock had previously closed at $8.10.
Analyst Upgrades and Downgrades
ROIV has been the subject of a number of research reports. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 14th. Citigroup raised their target price on shares of Roivant Sciences from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, January 5th. The Goldman Sachs Group raised their target price on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, January 19th. JPMorgan Chase & Co. raised their price target on shares of Roivant Sciences from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, February 13th. Finally, SVB Leerink raised their target price on shares of Roivant Sciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Monday, December 19th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Roivant Sciences has a consensus rating of “Buy” and a consensus price target of $12.50.
Roivant Sciences Stock Performance
The company has a market cap of $6.11 billion, a PE ratio of -4.52 and a beta of 1.26. The firm’s fifty day moving average is $8.39 and its 200 day moving average is $6.01. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 0.26.
Insider Transactions at Roivant Sciences
Hedge Funds Weigh In On Roivant Sciences
A number of hedge funds have recently modified their holdings of the business. California State Teachers Retirement System grew its position in Roivant Sciences by 0.7% in the 3rd quarter. California State Teachers Retirement System now owns 238,961 shares of the company’s stock valued at $769,000 after buying an additional 1,703 shares during the last quarter. Pathstone Family Office LLC boosted its position in shares of Roivant Sciences by 6.1% during the 3rd quarter. Pathstone Family Office LLC now owns 38,488 shares of the company’s stock worth $124,000 after purchasing an additional 2,227 shares in the last quarter. Hsbc Holdings PLC raised its stake in shares of Roivant Sciences by 25.4% during the 1st quarter. Hsbc Holdings PLC now owns 14,684 shares of the company’s stock worth $71,000 after buying an additional 2,978 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Roivant Sciences by 3.7% during the 4th quarter. Legal & General Group Plc now owns 101,495 shares of the company’s stock worth $811,000 after buying an additional 3,578 shares during the last quarter. Finally, Arizona State Retirement System raised its stake in shares of Roivant Sciences by 5.7% during the 4th quarter. Arizona State Retirement System now owns 79,504 shares of the company’s stock worth $635,000 after buying an additional 4,276 shares during the last quarter. 52.66% of the stock is currently owned by hedge funds and other institutional investors.
Roivant Sciences Company Profile
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.